Ember merged with Mariel Therapeutics in March 2015. The combined entity, known as Ember Therapeutics, Inc., is focused on developing regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport syndrome.

Year Invested: 2011
Location: New York, New York
Visit: embertx.com